GLPG0778/555 - Immuno & Inflammatory
GlaxoSmithKline has exercised its option to exclusively license investigational compound GLPG0778 and its corresponding back-up compound GLPG0555, both discovered and developed within GSKs immuno-inflammatory alliance with Galapagos. GSK will have the right to continue the clinical development of these compounds. GlaxosmithKline initiated three Phase 2 studies with GSK2586184 in systemic lupus erythematosus, chronic plaque psoriasis, and ulcerative colitis. GSK2586184 is the second selective JAK1 molecule discovered by Galapagos in Phase 2 studies.
For more information about ongoing clinical trials for GSK2586184, please click here.